Application of SLE-DAS to assess subcutaneous belimumab efficacy in a cohort of systemic lupus erythematosus patients.

Fulvia CeccarelliLicia PicciarielloFrancesco NatalucciValeria MorettiFrancesca Romana SpinelliCristiano AlessandriFabrizio Conti

Published in: Clinical and experimental rheumatology (2024)

In this study we applied SLE-DAS to assess the efficacy of sc BLM, by analysing its over-time changes and by comparing its performance with SLEDAI-2k. Indeed, our results suggest the usefulness of this new activity index in a real-life setting.

Keyphrases

systemic lupus erythematosus
disease activity
end stage renal disease
rheumatoid arthritis
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis